ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
ADC Therapeutics will webcast its CEO’s September 11, 2026 Cantor conference fireside chat for investors, with replay access for about 30 days.
Rhea-AI Summary
ADC Therapeutics (ADCT)/b) announced that CEO Ameet Mallik will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on Friday, September 11, 2026, at 9:10 a.m. ET.A live webcast and a 30-day replay will be accessible via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Q2 earnings report | Negative | -15.0% | Reported Q2 results while raising concerns about LOTIS-5's regulatory path |
| Aug 06 | Conference call scheduling | Neutral | +5.6% | Scheduled the Q2 2026 results call and webcast for August 13 |
| Jul 01 | Employee inducement grant | Neutral | +4.4% | Granted 17,000 inducement-plan stock options to a newly hired employee |
| Jun 30 | Trial enrollment completion | Positive | +3.9% | Completed enrollment in 100-patient Phase 1b LOTIS-7 combination trial of ZYNLONTA |
| Jun 24 | Strategic reorganization | Negative | -7.0% | Announced 17% workforce reduction and about $10 million annualized savings |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with three event outcomes aligned with the announcement sentiment and two neutral announcements followed by gains.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).
ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.
Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia pathways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA® as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA® in the United States and foreign jurisdictions and into earlier lines of therapy; whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial data and potential compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA® plus glofitamab; our expected revenue growth in 2027 and the Company's ability to sustain or grow ZYNLONTA® revenue in the future; our expected cash runway into at least 2028 which assumes use of the minimum liquidity amount required to be maintained under its loan agreement covenants; our ability to comply with the terms of our indebtedness; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.
CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-the-2026-cantor-global-healthcare-conference-302866379.html
SOURCE ADC Therapeutics SA
FAQ
When will ADC Therapeutics (ADCT) present at the 2026 Cantor Global Healthcare Conference?
ADC Therapeutics will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Friday, September 11, 2026, at 9:10 a.m. ET in New York, NY.
How can investors access the ADC Therapeutics (ADCT) Cantor Global Healthcare Conference webcast?
Investors can access a live webcast of the ADC Therapeutics fireside chat via the Events & Presentations page in the Investors section of the company’s website at ir.adctherapeutics.com.
Will a replay of the ADC Therapeutics (ADCT) Cantor conference presentation be available?
Yes. A replay of the ADC Therapeutics fireside chat webcast will be available on the company’s Investors website for approximately 30 days after the event.